Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853-60.10.1056/NEJM199803263381301Search in Google Scholar

2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997; 315:1194-9.10.1136/bmj.315.7117.1194Search in Google Scholar

3. Sungkanuparph S, Kiertiburanakul S, Manosuthi W, Kiatatchasai W, Vibhagool A. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability. Int J STD AIDS. 2005; 16:243-6.10.1258/0956462053420121Open DOISearch in Google Scholar

4. Kiertiburanakul S, Sungkanuparph S, Rattanasiri S, Manosuthi W, Vibhagool A, Thakkinstian A. Virological and immunological responses of efavirenzbased HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3. J Med Assoc Thai. 2006; 89:1381-7.Search in Google Scholar

5. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosiscoinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr. 2006; 43:42-6.10.1097/01.qai.0000230521.86964.86Search in Google Scholar

6. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007; 5: 355-60.10.2174/157016207780636551Search in Google Scholar

7. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai. 2004; 87:760-7.Search in Google Scholar

8. Tin EE, Bowonwatanuwong C, Desakorn V, Wilairatana P, Krudsood S, Pitisuttithum P. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+ nevirapine) in treatment-naive adult HIV patients. Southeast Asian J Trop Med Public Health. 2005; 36: 362-9.Search in Google Scholar

9. Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health. 2006; 37: 704-15.Search in Google Scholar

10. Sungkanuparph S, Anekthananon T, Hiransuthikul N, Bowonwatanuwong C, Supparatpinyo K, Mootsikapun P, et al; Thai AIDS Society. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai. 2008; 1:925-35.Search in Google Scholar

11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 11 April 2010.Search in Google Scholar

12. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents - November 2009; 1-24. Available at http://www.who.int/HIV/pub/arv/rapid_advice_art.pdf. Accessed 11 April 2010.Search in Google Scholar

13. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIVinfected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006; 53:357-63.10.1016/j.jinf.2006.01.002Search in Google Scholar

14. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr. 2007; 45:595-6.10.1097/QAI.0b013e318061b5ebSearch in Google Scholar

15. Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, Thakkinstian A. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiarycare- based study. J Med Assoc Thai. 2004; 87: 1349-54.Search in Google Scholar

16. Sungkanuparph S, Wongprasit P, Manosuthi W, Atamasirikul K. Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting. Southeast Asian J Trop Med Public Health. 2008; 39: 863-6.Search in Google Scholar

17. Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, et al. UK Collaborative HIV Cohort (CHIC) Study. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007; 370:1923-8.10.1016/S0140-6736(07)61815-7Search in Google Scholar

18. de Beaudrap P, Etard JF, Guèye FN, Guèye M, Landman R, Girard PM, et al; ANRS 1215/1290 Study Group. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. AIDS Res Hum Retroviruses. 2008; 24:753-60.10.1089/aid.2007.029518507521Search in Google Scholar

19. Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, et al; Asia Pacific HIV Observational Database (APHOD). Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr. 2009; 50: 513-20.10.1097/QAI.0b013e31819906d3275268119408354Search in Google Scholar

20. Sungkanuparph S, Chakriyanuyok T, Butthum B. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J Infect. 2008; 56:40-3.10.1016/j.jinf.2007.10.005Search in Google Scholar

21. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, et al; Staccato Thailand Study Group. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther. 2008; 13:375-80.10.1177/135965350801300302Search in Google Scholar

22. Duncombe C, Kerr SJ, Ruxrungtham K, Dore GJ, Law MG, Emery S, et al. HIV disease progression in a patient cohort treated via a clinical research network in a resource limited setting. AIDS. 2005; 19:169-78.10.1097/00002030-200501280-00009Open DOISearch in Google Scholar

23. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, S˜rensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007; 146:87-95.10.7326/0003-4819-146-2-200701160-00003Search in Google Scholar

24. CDC. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41(RR-17):1-19.Search in Google Scholar

25. Supparatpinyo K, Chiewchanvit S, Hirunsri P, Uthammachai C, Nelson KE, Sirisanthana T. Penicillium marneffei infection in patients infected with human immunodeficiency virus. Clin Infect Dis. 1992; 14: 871-4.10.1093/clinids/14.4.871Open DOISearch in Google Scholar

26. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4:e5575.10.1371/journal.pone.0005575Search in Google Scholar

27. Sterne JA, May M, Costagliola D, de Wolf F, Phillips A, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373:1352-63.10.1016/S0140-6736(09)60612-7Search in Google Scholar

28. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008; 22:841-8.10.1097/QAD.0b013e3282f7cb76361846018427202Search in Google Scholar

29. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008; 197:1133-44.10.1086/58671318476292Search in Google Scholar

30. Severe P, Pape J, Fitzgerald DW. A randomized clinical trial of early versus standard antiretroviral therapy for HIV-infected patients with a CD4 T cell count of 200-350 cells/mL (CIPRAHT001). Presented at the 46th ICAAC, San Francisco, September, 2009 (Abstract H-1230c).Search in Google Scholar

31. Chaiwarith R, Salee P, Kotarathitithum W, Sirisanthana T, Supparatpinyo K. Long-term CD4 cell count recovery among Thai naive HIV-infected patients initiating HAART at low CD4 cell count. Curr HIV Res. 2009; 7: 340-5.10.2174/15701620978834790319442132Search in Google Scholar

32. Manosuthi W, Sungkanuparph S, Vibhagool A, Rattanasiri S, Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med. 2004; 5:105-9.10.1111/j.1468-1293.2004.00195.x15012650Search in Google Scholar

33. Chuapai Y, Kiertiburanakul S, Malathum K, Sungkanuparph S. Lipodystrophy and dyslipidemia in human immunodeficiency virus-infected Thai patients receiving antiretroviral therapy. J Med Assoc Thai. 2007; 90:452-8.Search in Google Scholar

34. Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004; 87:605-11.Search in Google Scholar

35. Manosuthi W, Sungkanuparph S, Thakkinstian A, Vibhagool A, Kiertiburanakul S, Rattanasiri S, et al. Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. AIDS. 2005; 19: 1481-6.10.1097/01.aids.0000183630.27665.3016135901Search in Google Scholar

36. Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006; 43: 253-5.10.1086/50521016779754Open DOISearch in Google Scholar

37. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010; 362:697-706.10.1056/NEJMoa0905848307622120181971Search in Google Scholar

38. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. J Infect. 2006; 52:188-94.10.1016/j.jinf.2005.05.01015992932Search in Google Scholar

39. Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. AIDS. 2006; 20: 131-2.10.1097/01.aids.0000196181.18916.9b16327334Open DOISearch in Google Scholar

40. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al; N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009; 48:1752-9.10.1086/59911419438397Open DOISearch in Google Scholar

41. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, et al. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis. 2007; 44:141-4.10.1086/51007817143831Open DOISearch in Google Scholar

42. Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Yamada N, et al. Pharmacokinetics and 48 weeks efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-Tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008; 13: 529-36.10.1177/135965350801300414Search in Google Scholar

43. Hammer SM, Saag MS, Schechter M, Montaner JSG, Schooley RT, Jacobsen DM, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA. 2008; 300:555-70.10.1001/jama.300.5.55518677028Search in Google Scholar

44. Raboud JM, Rae S, Hogg RS, Yip B, Sherlock CH, Harrigan PR, et al. Suppression of plasma viral load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J Infect Dis. 1999;180:1347-50.10.1086/31499810479170Search in Google Scholar

45. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003; 163:2187-95.10.1001/archinte.163.18.218714557216Search in Google Scholar

46. Mee P, Fielding KL, Charalambous S, Churchyard GL, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008; 22:1971-7.10.1097/QAD.0b013e32830e4cd818784460Open DOISearch in Google Scholar

47. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis. 2008; 8:89.10.1186/1471-2334-8-89245918418601727Search in Google Scholar

48. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009; 49:454-62.10.1086/600396485942719569972Open DOISearch in Google Scholar

49. Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanuphak P, Duncomb C. HIV-NAT Study Team. Monitoring the toxicity of antiretroviralSearch in Google Scholar

therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother. 2006; 58:637-44.10.1093/jac/dkl31316895939Search in Google Scholar

50. Sungkanuparph S, Kiertiburanakul S, Apisarnthanarak A, Malathum K, Sathapatayavongs B. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. Int J STD AIDS. 2007; 18:832-4.10.1258/09564620778271699218073016Open DOISearch in Google Scholar

51. Homsanit M, Nelson KE, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J Jr. Body shape and metabolic abnormalities in Thai HIV-infected patients. AIDS Res Hum Retroviruses. 2007; 23:1314-21.10.1089/aid.2007.001318184072Search in Google Scholar

52. Hiransuthikul N, Hiransuthikul P, Kanasook Y. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors. Southeast Asian J Trop Med Public Health. 2007; 38:69-77.Search in Google Scholar

53. Ananworanich J, Nuesch R, Côté HC, Kerr SJ, Hill A, Jupimai T, Laopraynak N, et al. Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine-a Staccato trial substudy. J Antimicrob Chemother. 2008; 61:1340-3.10.1093/jac/dkn09718339636Search in Google Scholar

54. Kerr SJ, Duncombe C, Avihingsanon A, Ananworanich J, Boyd M, Sopa B, et al. Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. J Int Assoc Physicians AIDS Care (Chic Ill). 2007; 6:36-46.10.1177/154510970629594617329503Search in Google Scholar

55. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS. 2003; 17:2129-31.10.1097/00002030-200309260-00018Open DOISearch in Google Scholar

56. Manosuthi W, Chaovavanich A, Tansuphaswadikul S, Prasithsirikul W, Inthong Y, Chottanapund S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resourcelimited setting. J Infect. 2007; 55:464-9.10.1016/j.jinf.2007.07.002Search in Google Scholar

57. Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009; 49:931-4.10.1086/605497Search in Google Scholar

58. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M; IeDEA Southern and Central Africa. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010; 10:251-61.10.1016/S1473-3099(10)70026-8Search in Google Scholar

59. Marais S, Wilkinson RJ, Pepper DJ, Meintjes G. Management of patients with the immune reconstitution inflammatory syndrome. Curr HIV/AIDS Rep. 2009; 6:162-71.10.1007/s11904-009-0022-z19589302Search in Google Scholar

60. Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis. 2007; 11: 413-6.10.1016/j.ijid.2006.11.00317331776Open DOISearch in Google Scholar

61. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixeddose combination of Stavudine, Lamivudine, and Nevirapine fails. Clin Infect Dis. 2007; 44:447-52.10.1086/51074517205457Search in Google Scholar

62. Nelson M, Arasteh K, Clotet B, Cooper DA, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1- infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005; 40:404-12.10.1097/01.qai.0000185314.56556.c316280694Search in Google Scholar

63. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic Ill). 2006; 5:152-6.10.1177/154510970629428817101807Search in Google Scholar

64. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. J Clin Virol. 2008; 41:310-3.10.1016/j.jcv.2007.12.01518316243Search in Google Scholar

65. Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, et al; HOPS (HIV Outpatient Study) Investigators. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann Intern Med. 2009; 151:73-84.10.7326/0003-4819-151-2-200907210-0000319620160Search in Google Scholar

66. Walmsley SL, Katlama C, Lazzarin A, Arestéh K, Pierone G, Blick G, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr. 2008; 47: 429-40.10.1097/QAI.0b013e318160a52918176328Search in Google Scholar

67. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C. Study Team. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir +saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2007; 8: 529-35.10.1111/j.1468-1293.2007.00506.x17944686Search in Google Scholar

68. van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingson A, et al. HIV-NAT 019 Study Team. Pharmacokinetics and short-term efficacy of a doubleboosted protease inhibitor regimen in treatment-naive HIV-1-infected adults. J Antimicrob Chemother. 2008; 61:1145-53.10.1093/jac/dkn05018285316Search in Google Scholar

69. Manosuthi W, Sungkanuparph S, Ruxrungtham K, Prasithsirikul W, Athichathanabadi C, Tantisiriwat W, et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr. 2008; 47:127-9.10.1097/QAI.0b013e318157b0da236591218156991Search in Google Scholar

70. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009; 17:138-45.Search in Google Scholar

71. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO Trial. Clin Infect Dis. 2009; 49: 1441-9.10.1086/63021019814627Search in Google Scholar